Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document the biotechnology company's acellular tissue platform, listed redeemable warrants and material corporate events. Form 8-K reports cover Nasdaq listing-compliance notices and amendments to distribution arrangements for the 6 millimeter acellular tissue engineered vessel-tyod, including worldwide development, commercialization and regulatory rights. Proxy materials cover board and shareholder voting matters, executive compensation, equity awards and governance. The filing record also identifies HUMAW as redeemable warrants, each whole warrant exercisable for one share of common stock at $11.50, traded on Nasdaq.
Humacyte, Inc. is asking stockholders at its virtual annual meeting on June 9, 2026 to approve six items, including electing three Class II directors and an advisory vote on executive pay and its frequency. Stockholders will also vote on ratifying PricewaterhouseCoopers LLP as auditor for 2026 and increasing authorized common stock from 350,000,000 to 550,000,000 shares via a charter amendment. Shares outstanding were 222,019,108 as of April 23, 2026, the record date. The proxy outlines governance practices, committee structures, and 2025 compensation, including bonuses paid at 80% of target and significant stock option and RSU grants to senior executives.
Humacyte, Inc. and Fresenius Medical Care have amended their 2018 distribution agreement for Symvess, an acellular tissue engineered vessel. Humacyte now has exclusive rights to distribute Symvess outside the U.S., while Fresenius Medical Care Holdings, Inc. will receive low-single-digit royalties on ex-U.S. net sales.
Existing terms for U.S. distribution remain unchanged. Fresenius Medical Care Holdings, Inc. and its parent, Fresenius Medical Care, report beneficial ownership of 18,312,735 shares of Humacyte common stock, representing 8.4% of the class, all with shared voting and dispositive power.
Humacyte, Inc. entered a Third Amendment to its distribution agreement with Fresenius Medical Care, giving Humacyte the sole right to develop, manage regulatory matters for, and commercialize its 6 millimeter acellular tissue engineered vessel, branded Symvess, on a worldwide basis.
In return, Humacyte will pay Fresenius low-single-digit royalties on net sales of Symvess outside the U.S., after a two-year royalty-free period following launch in each country, while existing U.S. royalty rates from mid-single digits to low double digits remain in place and Fresenius stays obligated to adopt Symvess as a standard of care where supported. Humacyte highlights that this realignment supports its planned international expansion and potential indication-specific partnerships, while Symvess currently holds FDA approval only for extremity vascular trauma and remains investigational for other uses.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on September 17, 2025. The amendment names the parties as Humacyte Global, Inc., Humacyte, Inc. and the purchasers TPC Investments III LP, TPC Investment Solutions LP and Hook SA LLC.
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.